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Abstract
Background: Methylprednisolone (MPD) is a rapid acting highly effective cluster headache preventive and also
suppresses the recurrence of migraine attacks. Previously, we could demonstrate that elevated CGRP plasma levels
in a cluster headache bout are normalized after a course of high dose corticosteroids. Here we assess whether MPD
suppresses interleukin-1β (IL-1β)- and prostaglandin E2 (PGE2)-induced CGRP release in a cell culture model of
trigeminal ganglia cells, which could account for the preventive effect in migraine and cluster
headache. Metoprolol(MTP), a migraine preventive with a slow onset of action, was used for comparison.
Methods: Primary cultures of rat trigeminal ganglia were stimulated for 24 h with 10 ng/ml IL-1β or for 4 h with
10 μM PGE2 following the exposure to 10 or 100 μM MPD or 100 nM or 10 µM MTP for 45 min or 24 h. CGRP was
determined by using a commercial enzyme immunoassay.
Results: MPD but not MTP blocked IL-1β-induced CGRP release from cultured trigeminal cells. PGE2-stimulated
CGRP release from trigeminal ganglia cell culture was not affected by pre-stimulation whether with MPD or MTP.
Conclusion: MPD but not MTP suppresses cytokine (IL-1β)-induced CGRP release from trigeminal ganglia cells. We
propose that blockade of cytokine mediated trigeminal activation may represent a potential mechanism of action
that mediates the preventive effect of MTP on cluster headache and recurrent migraine attacks.
Keywords: Cluster headache, Migraine, Trigeminal ganglia cells, Calcitonin gene related peptide,
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Background
The trigeminal system and the neuropeptide calcitonin
gene-related peptide (CGRP) are key players in migraine
and cluster headache pathophysiology. Activation of peri-
vascular trigeminal nerves within the meninges causes the
release of CGRP [1, 2]. CGRP plasma levels were elevated
during migraine and cluster headache attacks and effective
attack treatment led to the normalization of CGRP levels
[3, 4]. The release of CGRP contributes to vasodilatation,
neurogenic inflammation, transmission of pain signals and
central sensitization [5]. These mechanisms seem to be of
significance in migraine pathophysiology and might also
be involved in cluster headache pathophysiology.
CGRP plasma levels may also serve as biomarkers for
primary headaches. Patients with episodic and chronic
migraine demonstrate elevated CGRP plasma levels be-
tween attacks [6]. Recently, we could demonstrate that
CGRP plasma levels are elevated interictally in episodic
cluster headache patients in the bout and that these levels
are reduced after short term prophylaxis with corticoste-
roids [7]. We hypothesized that elevated CGRP plasma
levels in a cluster bout might represent a hyperactive state
of the trigeminal nervous system. Suppression of trigemi-
nal hyperactivity could be a consequence of corticosteroid
therapy, which in turn leads to the suppression of cluster
headache attacks. However, our study could not exclude
that altered CGRP levels were rather a consequence than
the cause of the reduced attack frequency.
Previously, we observed in cultured trigeminal ganglia
cells that interleukin 1β (IL-1β) and prostaglandin E2
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(PGE2) induce CGRP release in a cyclooxygenase-2
dependent pathway [8]. Cytokines and especially IL-1β
have been linked to migraine [9, 10] and cluster head-
ache [11] and an involvement of pro-inflammatory cyto-
kines in the pathophysiology of primary headaches is
probable.
To determine whether corticosteroids may influence
trigeminal activation directly, we studied the effects of
corticosteroids on CGRP release in this trigeminal gan-
glia cell model using IL-1β and PGE2 for stimulation. In
addition to short-term cluster headache prophylaxis
methylprednisolone (MPD) is also used to abort a mi-
grainous state or to prevent the recurrence of migraine
attacks [12]. Therefore, we compared the effects of
MPD, a drug with rapid onset of action, with the slowly
acting migraine preventive metoprolol (MTP) on CGRP
release in this model.
Methods
Animals
We used 3-day-old male and female Sprague Dawley rats
(Charles River, Sulzheim, Germany). All animals were kept
under standard laboratory housing conditions with a 12 h
light–dark cycle and with an adult female Sprague Dawley
rat (Charles River, Sulzheim, Germany) with free access to
food and water. For cell culture procedures newborn ani-
mals were anaesthetized with an isoflurane vaporizer (4 %)
and decapitated. All animal work was carried out in
accordance with the European Communities Council
Directive of 24 November 1986 (86/609/EEC) regarding
the care and use of animals for experimental procedures.
The sacrifice of the rats and extraction of their brains was
approved by and reported to the Landesamt für Gesundheit
und Soziales Berlin (LaGeSo; T0322/96).
Cell culture
Trigeminal ganglia cell culture was established as previ-
ously described by our group [8]. In brief, trigeminal gan-
glia were dissected from 3 day old male and female
Sprague Dawley rats (Charles River, Sulzheim, Germany).
The cells were incubated for 90 min at 37 °C in 10 ml dis-
sociation medium (modified eagles medium; Biochrom,
Berlin, Germany; with 10 % bovine serum, 10 mM HEPES,
44 mM glucose, 100 U penicillin + streptomycin, 2 mM
glutamine, 100 IE insulin/l) containing collagenase/dispase
(final concentration 100 μg/ml) (Boehringer Mannheim,
Germany), rinsed twice with phosphate buffered saline
(PBS) 0.1 M and again incubated with trypsin/EDTA
(0.05 %/0.02 % w/v in PBS) for 30 min for dissociation.
Subsequently, cells were rinsed twice with PBS and once with
dissociation medium, dissociated by Pasteur pipette and pel-
leted by centrifugation at 2100 x g for 2 min at 21 °C. After
suspension in starter medium (Invitrogen, Karlsruhe,
Germany) plus 1 % penicillin/streptomycin, 0,25 % L-
glutamine, 2 % B27-supplement, 0,1 % 25 mM glutamate,
2.5 mM calcium chloride and 100 ng/ml nerve growth
factor-β, cells were plated in 24 well plates and filled to
500 μl with starter medium at a density of 0.5 x 10−6 cells/
cm2 (equates approximately 2 ganglia/well). Wells were
pretreated by incubation with poly-l-lysin (5 % w/v in
PBS) for 90 min at 4 °C, then rinsed with PBS, followed by
incubation with coating medium (dissociation medium
with 1 % w/v collagen G) for 90 min at 37 °C in the incu-
bator. After that, the wells were rinsed twice with PBS and
filled with starter medium in which cells were seeded.
Cytosine arabinoside (final concentration 10 μM; Sigma
Aldrich, Munich, Germany) was added at day 1 and day 3
to minimize growth of non-neuronal cells. Cultures were
kept at 37 °C and 5 % CO2 and fed with neurobasal
medium+ B27 medium every second day by replacing
50 % of the medium. Condition of cultures was assessed
by light microscopy. Stimulation experiments were per-
formed on day 6.
CGRP determination by enzyme immunoassay
After 6 days in culture the medium was gently removed
and replaced with fresh medium without nerve growth
factor to exclude effects of nerve growth factor on pro-
tein release. 1 h later cells were stimulated for 24 h with
IL-1β (10 ng/ml), 4 h with PGE2 (10 μM) or equal vol-
ume of vehicle (PBS 0.1 M). For inhibition studies cells
were pre-incubated with MPD (10 μM or 100 μM),
MTP (100 nM or 10 μM) or PBS 45 min or 24 h prior
to simulation with vehicle (PBS), IL-1β or PGE2. Imme-
diately before the stimuli 50 μl supernatant of each well
were removed to assess baseline CGRP levels. At the
end of the stimulation supernatants of two dishes were
pooled and used for CGRP determination with a specific
CGRP enzyme immunoassay (SPIbio, Montigny le
Bretonneux, France) as recommended by the manufac-
turer. For each experiment, one set of wells was treated
with 60 mM KCl to determine the responsiveness of the
cultures to an established depolarizing stimulus [13].
Cultures that exhibited a response less than 2-fold on
CGRP release after the depolarizing stimulus were not an-
alyzed. CGRP release was determined in pg/ml as absolute
increase over baseline values in the corresponding two
wells (CGRP levels after stimulation – baseline CGRP
levels before stimulation). All samples were measured in
duplicates. Each experimental condition was repeated in
at least seven independent experiments.
Statistical analysis
Due to small sample size nonparametric statistics were
used. Differences of CGRP values between groups were
analysed with the Kruskal-Wallis H test. If this test
showed statistical significance pairwise comparison was
performed using the Mann–Whitney U test. Resulting
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p-values were adjusted for multiple comparisons using
the Bonferroni-Holm method. Corrected p < 0.05 was
considered statistically significant. All statistical tests
were performed with the SPSS 20 statistical software
(SPSS, Chicago, IL, USA). Data are shown as mean ±
standard error of the mean (SEM).
Results
In a first step we investigated the effect of MPD on basal
and stimulated CGRP release in cultures of rat trigemi-
nal ganglia cells. Cultures were pretreated with vehicle
(PBS) or MPD (10 or 100 μM) for 45 min followed by
stimulation with PBS or IL-1β (10 ng/ml) for 24 h.
A Kruskal-Wallis H test showed that there was a sta-
tistically significant difference in CGRP levels between
the different stimulations (χ2 (3) = 10.270, p = 0.016).
Pairwise comparison using the Mann–Whitney U test
with correction for multiple comparison (Bonferroni-
Holm method) revealed that stimulation of trigemi-
nal ganglia cells with IL-1β led to a significantly
increased CGRP release compared to control (PBS)
(IL-1β: 638 ± 189 SEM pg/ml vs. PBS: 295 ± 48 SEM
pg/ml; n = 9; p = 0.031). Administration of 10 μM or
100 μM MPD into the culture (45 min before stimulation
with IL-1β) led to a statistical significant suppression
of IL-1β-stimulated CGRP release (310 ± 47 SEM pg/ml;
p = 0.022 (10 μM) and 264 ± 74 SEM pg/ml; p = 0.012
(100 μM); n = 9). In contrast, pretreatment of cultures
with MPD for 45 min itself without adding IL-1β did not
significantly change the amount of CGRP release in con-
trols (PBS exposure solely) (Fig. 1).
Subsequently we tested if PGE2-induced CGRP release
is also altered by pre-stimulation with MPD. There was
a statistically significant difference in the CGRP levels
between different stimulations as determined by a
Kruskal-Wallis H test (χ2 (3) = 10.318, p = 0.016) Stimu-
lation of cultured trigeminal ganglia cells with PGE2
(10 μM) for 4 h led to significantly increased CGRP
levels in the supernatant compared to PBS (324 ± 93 vs.
33 ± 7 pg/ml SEM; n = 8, p < 0.0001). However, the ad-
ministration of MPD 10 μM (n = 8) or 100 μM (n = 7) to
trigeminal ganglia cells 45 min prior to PGE2 stimulation
did not alter CGRP release compared to pre-stimulation
with vehicle (PBS) (p > 0.05). The extension of MPD ex-
posure to 24 h did neither affect PGE2-induced CGRP
release (n = 8) (Fig. 2).
In a second step we assessed whether the exposure to
MTP had any effect on IL-1β- or PGE2-induced CGRP
release. In contrast to MPD, MTP did not change sig-
nificantly the amount of stimulus-induced CGRP release
in this model. There was a trend towards lower CGRP
levels in cultures pretreated with MTP 45 min prior to
PGE2 exposure. However, the results did not reach stat-
istical significance (p = 0.14; n = 9), (Figs. 3 and 4). In
Fig. 1 Pretreatment with methylprednisolone (MPD) suppressed IL-1β-
stimulated CGRP release in trigeminal ganglia cell culture. Kruskal-Wallis
test followed by Mann–Whitney U test with p-values adjusted for
multiple comparisons using the Bonferroni-Holm method was used to
determine significant differences. IL-1β (10 ng/ml) but not vehicle
stimulation (PBS) resulted in significantly enhanced CGRP levels in the
supernatant of cultured trigeminal ganglia cells after 24 h (*p = 0.031
vs. vehicle). Exposure to MPD 10 μM or 100 μM 45 min prior to
stimulation with IL-1β blocked CGRP release significantly compared to
pre-treatment with PBS (# p = 0.022 (10 μM) and p = 0.012 (100 μM).
CGRP levels are shown in mean pg/ml ± SEM, n = 9
Fig. 2 Pretreatment with methylprednisolone (MPD) did not affect
PGE2-stimulated CGRP release in trigeminal ganglia cell culture.
CGRP secretion was determined after pretreatment with PBS or MPD
(10 μM or 100 μM) for 45 min or 24 h followed by stimulation with
PGE2 (10 μM) or vehicle for 4 h. CGRP release was significantly
enhanced after PBS + PGE2 (* p < 0.0001, compared to PBS + PBS).
CGRP levels were not altered by pre-stimulation with MPD for
45 min or 24 h (p > 0.05, compared to pre-treatment with PBS).
CGRP levels are shown in mean pg/ml ± SEM, n = 7–8
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preliminary experiments (n = 4) higher concentrations of
MTP (100 μM) did neither alter CGRP release in this
model.
Discussion
In this study MPD blocked IL-1β-induced CGRP secre-
tion in a trigeminal ganglion cell culture model. MPD
had no effect on PGE2-stimulated CGRP release. Vehicle
treated CGRP release in cultured trigeminal ganglia cells
was not affected by MPD. The migraine preventive MTP
had no effect on IL-1β- or PGE2-stimulated CGRP release.
In contrast, previous studies in a similar cell culture model
showed that the migraine preventives topiramate and
botulinum toxin type A blocked CGRP release in cultured
trigeminal ganglia cells when stimulated with KCl, capsa-
icin, protons or nitric oxide [14, 15].
Concentrations and time points for stimulation with
IL-1β or PGE2 were determined by previous results in
this model with maximum CGRP release at these values
[8]. Doses for MPD (10 or 100 μM) and MTP (100 nM
and 10 μM) used in this experimental study were de-
rived from human data on serum concentrations after
applying therapeutically beneficial doses of the drugs. In-
take of 80 mg oral methylprednisolone leads to a serum
concentration of 7 μM [16]. Intravenous administration
of 1000 mg methylprednisolone results in serum con-
centrations between 16 and 77 μM [17]. Mean serum
concentrations of metoprolol after oral application of
100 mg were stated with 136 nM [18]. To assess a max-
imal effect we chose the higher metoprolol dose equal to
the effective dose of methylprednisolone (10 μM).
For pre-stimulation with MTP and MPD we chose
45 min and 24 h before the exposure to PGE2 (4 h) to as-
sess the acute effect of stimuli as well as effects that may
be mediated through longer acting mechanisms ( e.g. gene
expression). Due to the long exposure to IL-1β (24 h) pre-
stimulation was restricted to 45 min in these experiments.
Primary trigeminal afferents are a major source of
CGRP release into the extracerebral circulation [19]. Ac-
tivation of trigeminal ganglia afferents and subsequent
release of CGRP is thought to play a prominent role in
the pathophysiology of migraine [20] and cluster head-
ache [21, 22] pathophysiology. The pro-inflammatory
cytokine IL-1β and other cytokines are elevated in mi-
graine [9, 10] and cluster headache patients [11, 23, 24].
The cytokines IL-1β and tumor necrosis factor alpha in-
duce CGRP release in cultured trigeminal ganglia cells
[8, 25]. The involvement of immunological mechanisms
in primary headaches is possible but the role of cyto-
kines in headache pathophysiology remains incompletely
understood.
Cytokines are proteins that are released by glial cells
in proximity to peripheral and central neurons. They are
involved in pro-inflammatory signaling pathways and
Fig. 3 Exposure to metoprolol (MTP) did not affect IL-1β-stimulated
CGRP release in trigeminal ganglia cell culture. CGRP secretion was
determined 45 min after pretreatment with MTP (100 nM and 10 μM)
respectively PBS followed by a 24 h exposure to PBS or IL-1β (10 ng/
ml). IL-1β stimulation for 24 h led to a significant CGRP release
compared to vehicle stimulation (* p = 0.042) which was not altered
by pre-treatment with MTP (100 nM or 10 μM) (p > 0.05, compared to
pre-treatment with PBS). CGRP levels are shown in mean
pg/ml ± SEM, n= 9
Fig. 4 Pretreatment with metoprolol (MTP) did not affect PGE2-
stimulated CGRP release in trigeminal ganglia cell culture. CGRP
secretion was determined 45 min or 24 h after pretreatment with
PBS, MTP 100 nM or MTP 10 μM followed by a 4 h exposure to PBS
or PGE (10 μM). Stimulation with PGE2 resulted in an induction of
CGRP release (* p < 0.0001 resp. 0.015, compared to treatment with
PBS), which was not altered by previous exposure to MTP (100 nM
or 10 μM) (p > 0.05, compared to pre-treatment with PBS). CGRP
levels are shown in mean pg/ml ± SEM, n = 9
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represent key elements in the induction and mainten-
ance of pain [26–30]. Increased cytokine expression and
pro-inflammatory protein synthesis are both patho-
physiological components for the development and
maintenance of peripheral and central sensitization.
Both mechanisms are important in the pathophysi-
ology of migraine [26, 31, 32]. CGRP itself differen-
tially regulates cytokine secretion from cultured
trigeminal ganglion glia cells. In CGRP treated
cultures secreted levels of some cytokines (e.g. IL-β)
increased while others such as tumor necrosis factor
alpha decreased. These results point to a paracrine
trigeminal activation due to CGRP release from tri-
geminal ganglia neurons and glial cytokine secretion that
may lead to an inflammatory loop, which could account
for sustained sensitization of second-order trigeminal neu-
rons [33]. Chronically sensitized central nociceptive neu-
rons are supposed to contribute to the development of
chronic migraine and its resistance to treatment [34].
In contrast to IL-1β-induced CGRP release, PGE2-in-
duced CGRP release was not affected by prior exposure
to MPD. Previously, we demonstrated that IL-1β in-
duced CGRP release in trigeminal ganglia cells is
dependent on COX-2 induction [8]. Methylprednisolone
prevents PGE2 formation by suppression of COX-2
activity [35]. If inhibition of CGRP release by methyl-
prednisolone is mediated through the prevention of
PGE2 formation, it is feasible that direct induction of
CGRP release by PGE2 cannot be blocked by methyl-
prednisolone. In a recent clinical study, we demonstrated
the effect of MPD on CGRP release in episodic cluster
headache patients in an active bout. A three day pulse
therapy with 1000 mg MPD per day led to the
normalization of interictally elevated CGRP plasma
levels in parallel to the suppression of headache attacks
[7]. We extend this observation with our experimental
findings in a cell culture of trigeminal ganglia cells. This
data support the hypotheses that corticosteroids might
exert their preventive action in migraine and cluster
headache by the inhibition of trigeminal activation,
which is necessary for the initiation of a headache attack.
Blockade of trigeminal neurotransmitter secretion could
account for prevention of central sensitization and trig-
gering of headache attacks.
Metoprolol, a migraine preventive with slow onset
of action had no effect in this experimental model.
MTP seems to mediate its prophylactic effect through
an alternative mode of action on possible non-
inflammatory mechanisms and not on a cellular level
in the trigeminal ganglion. The precise mechanism of
action of metoprolol in migraine prophylaxis is not
known, but modification of cortical excitability by
inhibiting central β-receptors most likely contributes
to its preventative effects [36–38].
Conclusions
Pretreatment with MPD blocked IL-1β-, but not PGE2-
induced CGRP release in cultured primary trigeminal
ganglia cells. Based on our findings, we propose that
MPD used for short-term cluster headache prophylaxis
or prevention of migraine recurrence might act via the
suppression of cytokine mediated trigeminal activation.
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